Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Enclomiphene and LGD-4033 Interaction: Compatible | Peptide Database

Compound Profiles Enclomiphene Selective Estrogen Receptor Modulator | Testosterone & Fertility Support Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH re

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Enclomiphene with LGD-4033?

Yes, Enclomiphene and LGD-4033 can generally be taken together. Enclomiphene is commonly used as post-cycle therapy (PCT) following LGD-4033 cycles to restore endogenous testosterone production. A typical PCT protocol is 12.5-25 mg/day enclomiphene for 4-6 weeks, starting approximately 2-3 days after the last LGD-4033 dose (the shorter half-life of LGD-4033 compared to RAD-140 means PCT can begin sooner). Some users also run low-dose enclomiphene on-cycle to mitigate suppression, though this approach is less studied.

Is Enclomiphene and LGD-4033 safe together?

Based on documented research, this combination is considered compatible. However, shared safety flags include: hepatotoxic, teratogenic. Monitor accordingly.

What are the interactions between Enclomiphene and LGD-4033?

Enclomiphene is commonly used as post-cycle therapy (PCT) following LGD-4033 cycles to restore endogenous testosterone production. A typical PCT protocol is 12.5-25 mg/day enclomiphene for 4-6 weeks, starting approximately 2-3 days after the last LGD-4033 dose (the shorter half-life of LGD-4033 compared to RAD-140 means PCT can begin sooner). Some users also run low-dose enclomiphene on-cycle to mitigate suppression, though this approach is less studied. This assessment has 90% confidence and is based on documented research data.

How should I time Enclomiphene and LGD-4033?

Enclomiphene has a half-life of ~10 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research. Demonstrated effectiveness against breast cancer cell lines. Induces necrosis of K-562 leukemia cells through HDM-2 binding. Shows selective targeting of melanoma cells. Most effective against cancers with high membrane HDM-2 expression. Model compound for studying cancer-selective therapies.

Source: peptide-db.com ↗

Research Indications

Restores endogenous testosterone production in men with secondary hypogonadism by increasing LH and FSH through hypothalamic estrogen receptor antagonism. Phase III trials demonstrated significant testosterone normalization. Provides a non-suppressive alternative to exogenous testosterone for men seeking to raise testosterone levels while maintaining natural HPTA function and fertility. Can serve as a standalone alternative to testosterone replacement therapy in appropriate candidates, particularly younger men or those concerned about fertility preservation. Accelerates recovery of the hypothalamic-pituitary-testicular axis after suppression from anabolic steroids or exogenous testosterone by rapidly increasing LH and FSH output. Helps restore natural testosterone production to baseline levels faster than unassisted recovery, reducing the hypogonadal window after cycle cessation. FSH elevation driven by enclomiphene supports Sertoli cell function and spermatogenesis, making it useful for men with oligospermia associated with secondary hypogonadism. Can be used as a bridge off TRT for men who wish to conceive, maintaining testosterone levels while restoring spermatogenesis.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Turinabol is exclusively administered orally as a 17-alpha-alkylated steroid. It is available in tablet form, typically in 10 mg and 20 mg doses from underground laboratories. The 17-alpha-methylation provides resistance to first-pass hepatic metabolism, enabling oral bioavailability but contributing to hepatic stress. Turinabol has moderate hepatotoxicity comparable to other methylated oral steroids, and liver support supplementation is recommended during use. Its 16-hour half-life allows for once- or twice-daily dosing, though split dosing provides more stable blood levels. Performance - Conservative 30-40 mg/day Split into 2 doses (morning and evening) Oral Performance - Standard 40-60 mg/day

Source: peptide-db.com ↗
Side effects

Common Side Effects

Hot flashes and increased sweating Leg cramps and muscle spasms Joint pain or stiffness Peripheral edema (mild swelling in extremities) Flu-like symptoms during initial weeks

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides